http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S6193120-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e760cdd8c0d6757c9aedfade9907308f
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7042
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-213
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7052
filingDate 1984-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9aa3122e43b21c8381c9d49164bb1504
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbed6dbb2c51bbc445b51cff6b361e94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6872fb5eefc258a580c1057d96cc5fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93da12ee0e45e0e094422f0992c6f6a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45881d87c8cbfda45cce6e21cd939553
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc61d30f1aa946c8609e8da00db5293d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95d5296603a018ae0566c5e8aae837ff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_deee4b041e1e4462d3b1bcd705968371
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_747a6295b3a755753095719db7c2050f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da5ed47e1007180b90b3030a62dc30ca
publicationDate 1986-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-S6193120-A
titleOfInvention Preventive and remedy for disseminated intravascular coagulation syndrome
abstract PURPOSE: To provide the titled drug containing a 2-substituted adenosine-3',5'- cyclic phosphoric acid or its salt. n CONSTITUTION: A preventive and remedy for disseminated intravascular coagulation (DIC) can be prepared by using the compound of formula (X is Cl or Br) or its salt as a component. The agent can be administered orally or parenterally, in the form of tablet, capsule, powder, granule, troche, suppository, etc., or of injection, suspended injection, etc. Dose: 5W400mg daily in 2W4 divided doses. The compound of formula can be prepared by (1) directly dehydrating 2-chloro- or bromo-adenosine-5'-phosphate to effect the 3',5'-cyclization of the phosphoric acid part (using dicyclohexylcarbodiimide, etc. as a dehydration agent), (2) converting the product to the active ester at the phosphono group, and (3) removing the ester group with a base. n COPYRIGHT: (C)1986,JPO&Japio
priorityDate 1984-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID428255235
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID70452145
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1004
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397643
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419555718
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393392
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID236074360
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54424873
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID236074363
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10868
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411550722

Total number of triples: 35.